Videos

Jonathan W. Riess, MD, medical director of thoracic oncology, University of California, Davis Comprehensive Cancer Center, discusses the phase 1b FAVOUR trial of furmonertinib in patients with advanced non–small cell lung cancer harboring EGFR Exon20 insertion mutations.

Manmeet Ahluwalia, MD, discusses the progress and initiatives of the Cancer Moonshot program.

Susan Bal, MD, discusses novel targets for relapsed/refractory multiple myeloma at the 2023 Annual Meeting.

Dr. Lunning explores the FDA-approved CD3- and CD20-targeting bispecifics in relapsed/refractory DLBCL, highlighting their potential impact on heavily pretreated patients.

A deep dive into treatment sequencing strategies in R/R DLBCL, sharing insights from clinical data and recently approved novel therapies.

Expert shares clinical perspectives and treatment considerations regarding use of later lines of therapy for patients with R/R diffuse large B-cell lymphoma.

In an interview with Targeted Oncology, Joshua Richter, MD, discusses how community oncologists can help manage disparities in diversity in clinical trials.

Aaron Gerds, MD, MS, shares hopes that combination therapies now in trials, along with other novel approaches further down the pipeline like monoclonal antibodies, vaccines, and cellular therapies will likely radically advance treatment over the next 5 to 10 years.

Aaron Gerds, MD, MS, reviews key safety concerns seen with JAK inhibitors for myelofibrosis treatment.

Aaron Gerds, MD, MS, explains the factors to consider when selecting an appropriate JAK inhibitor for patients with myelofibrosis.

When switching JAK inhibitors for myelofibrosis, Aaron Gerds, MD, MS, advises stopping ruxolitinib and starting the new JAK inhibitor the next day due to its short half-life, though tapering ruxolitinib over 1 week is recommended for patients on higher doses to avoid rebound symptoms; pacritinib and fedratinib have longer half-lives so a 1-week washout can be considered.

Aaron Gerds, MD, MS, explains that myelofibrosis patients on JAK inhibitors need regular monitoring of blood counts, liver enzymes, and cardiac events to check for reactivation.

Aaron Gerds, MD, MS, details the use of momelotinib in myelofibrosis treatment.

Aaron Gerds, MD, MS, outlines how first-line treatment choice for myelofibrosis depends on symptoms, spleen size, and blood counts, while second-line choice depends on prior side effects and medical history.

Yazan Madanat, MD, comments on the updates that were recently presented at ASH 2023 for the management of lower-risk MDS and discusses the impact of emerging therapies.

David Zhen, MD, provides advice to oncologists treating patients with upper gastric cancer and offers closing thoughts on the future treatment landscape, highlighting challenges and unmet needs.

Turning the focus to ongoing research, an expert on upper gastric cancer discusses novel targets being investigated in clinical trials and the evolving treatment landscape.

A medical oncologist discusses the treatment of patients with gastric adenocarcinoma who have progressed following treatment with immunotherapy.

Explanation of how these data apply to community oncologists.

Presenting real-world data on the efficacy and safety of teclistamab for R/R MM.

David Zhen, MD, provides clinical insights on the management of adverse events stemming from immunotherapy in patients with upper gastric cancer.

Expert perspectives on the role of immunotherapies in upper gastrointestinal cancers, highlighting the CheckMate 649 study investigating frontline nivolumab plus chemotherapy.

Discussion of the real-world effectiveness of teclistamab in R/R MM and the impact on treatment guidelines and practice.

Danai Dima, MD, further explores the patient characteristics in the R/R MM teclistamab real-world study.

A medical oncologist reviews the available frontline treatment options for patients with gastric adenocarcinoma.

David Zhen, MD, reviews the profile of a 60-year-old man with stage IV gastric adenocarcinoma and offers his initial impressions on the case.

A description and overview of teclistamab and its mechanism of action.

Expert insights into the evolving therapeutic landscape for newly diagnosed multiple myeloma, highlighting transplant eligibility, combination regimens, and emerging data.

Igor Astsaturov, MD, PhD, discusses the planned phase 1 trial of LP-184 in multiple advanced solid tumors and central nervous system cancers, including pancreatic cancer.